logo
Select company
Select metric
Ticker Information

Ticker

CTMX

Company Name

CYTOMX THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

CYTOMX THERAPEUTICS INC - Capital Expenditures to Operating Cash Flow Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

CTMX - CapEx/OCF Historical data
DateCapital ExpenditureCapital Expenditures to Operating Cash FlowNet Cash Flow - Operations
6/30/2025$ 245K0%$ -77.43M
3/31/2025$ 314K0%$ -81.23M
12/31/2024$ 310K0%$ -86.23M
9/30/2024$ 496K0%$ -88.29M
6/30/2024$ 486K0%$ -85.8M
3/31/2024$ 907K0%$ -91.43M
12/31/2023$ 840K0%$ -56.03M
9/30/2023$ 756K0%$ -35.47M
6/30/2023$ 1.16M0%$ -51.07M
3/31/2023$ 1.05M0%$ -60.13M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • CYTOMX THERAPEUTICS INC's latest trailing twelve months (TTM) CapEx/OCF stands at 0%.
  • Over the past 5 years, CYTOMX THERAPEUTICS INC's average CapEx/OCF has been 26.43%.
  • The median CapEx/OCF for CYTOMX THERAPEUTICS INC during this period was 26.43%
  • CYTOMX THERAPEUTICS INC reached its highest CapEx/OCF over the past 5 years at 43.91%.
  • The lowest CapEx/OCF recorded by CYTOMX THERAPEUTICS INC in the same timeframe 8.95%

CYTOMX THERAPEUTICS INC's CapEx/OCF vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

CapEx/OCF Benchmarks
CompanyCapEx/OCF
ARCT : ARCTURUS THERAPEUTICS HOLDINGS INC -RGNX : REGENXBIO INC -HRTX : HERON THERAPEUTICS INC -ADCT : ADC THERAPEUTICS SA -GLUE : MONTE ROSA THERAPEUTICS INC 13.94%YMAB : Y-MABS THERAPEUTICS INC -XNCR : XENCOR INC -NRC : NATIONAL RESEARCH CORP 56.49%SPOK : SPOK HOLDINGS INC 12.1%VNDA : VANDA PHARMACEUTICALS INC -

Definition of Capital Expenditures to Operating Cash Flow

[Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
CapEx / CF - Operations
(=) CapEx/OCF
CapEx/OCF for CYTOMX THERAPEUTICS INC is calculated as follows: CapEx [ $ 2.57M ] / CF - Operations [ $ -6.79M ]
(=) CapEx/OCF [ 0% ]

CTMX - Capital Expenditures to Operating Cash Flow, Last 5 years

8.95%

Minimum

Mar 31, 2021

43.91%

Maximum

Dec 31, 2020

26.43%

Average

26.43%

Median

CapEx/OCF Benchmark Analysis

The chart above depicts the distribution of CapEx/OCF for companies in the Total Stock Market. The average CapEx/OCF of the companies is 31.8% with a standard deviation of 29.52%.
The following table provides additional summary stats:
CapEx/OCF in the Market:
filtered constituents2.35K
min0.01%
max128%
average31.8%
median22.41%
std29.52%